The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer
Open accessAbstract
Purpose: To characterize changes in lean body mass (LBM) in men with prostate cancer receiving androgen-deprivation therapy (ADT). Patients and Methods: We prospectively evaluated LBM in a prespecified substudy of a randomized controlled trial of denosumab to prevent fractures in men receiving ADT for nonmetastatic prostate cancer. LBM was measured by total-body dual-energy x-ray absorptiometry at study baseline and at 12, 24, and 36 months. The analyses included 252 patients (132, denosumab; 120, placebo) with a baseline and at least one on-study LBM assessment. Patients were stratified by age (< 70 v ≥ 70 years) and by ADT duration (≤ 6 v > 6 months). Results: Median ADT duration was 20.4 months at study baseline. Mean LBM decreased significantly from baseline, by 1.0% at month 12 (95% CI, 0.4% to 1.5%; P < .001; n = 248), by 2.1% at month 24 (95% CI, 1.5% to 2.7%; P < .001; n = 205), and by 2.4% at month 36 (95% CI, 1.6% to 3.2%; P < .001; n = 168). Men age ≥ 70 years (n = 127) had significantly greater changes in LBM at all measured time points than younger men. At 36 months, LBM decreased by 2.8% in men age ≥ 70 years and by 0.9% in younger men (P = .035). Men with ≤ 6 months of ADT at study entry (n = 36) had a greater rate of decrease in LBM compared with men who had received more than 6 months of ADT at study entry (3.7% v 2.0%; P = .0645). Conclusion: In men receiving ADT, LBM decreased significantly after 12, 24, and 36 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frailty in Older Adults: Evidence for a Phenotype
Fried, L. P., Tangen, C. M., Walston, J., Newman, A. B., Hirsch, C., Gottdiener, J., Seeman, T., Tracy, R., Kop, W. J., Burke, G., et al. (2001) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/56.3.m146 · Cited by 24,907
Sarcopenia: European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., Martin, F. C., Michel, J.-P., Rolland, Y., Schneider, S. M., et al. (2010) · Age and Ageing · doi:10.1093/ageing/afq034 · Cited by 11,601
Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives
Rolland, Y., Czerwinski, S., van Kan, G. A., Morley, J. E., Cesari, M., Onder, G., Woo, J., Baumgartner, R., Pillard, F., Boirie, Y., et al. (2008) · The Journal of nutrition, health and aging · doi:10.1007/bf02982704 · Cited by 1,071
Sarcopenic obesity: A new category of obesity in the elderly
Zamboni, M., Mazzali, G., Fantin, F., Rossi, A., & Di Francesco, V. (2008) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.10.002 · Cited by 953 · cited 1×
“The loss of LBM in men receiving androgen-deprivation therapy (ADT) is often associated with an increase in fat mass, a combination referred to as sarcopenic obesity.(6,7) Definitions of sarcopenia have evolved over time; whereas early definitions focused on the effects of aging on LBM, later definitions incorporate t…”
BackgroundChanges in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697 · cited 1×
“The observation that LBM decreased during ADT is consistent with the results of several prior reports.(15,16,21-23) In two small prospective studies(15,16) of men initiating ADT for prostate cancer, LBM significantly decreased by 2.”
ResultSelf-citationSegal, R. J., Reid, R. D., Courneya, K. S., Sigal, R. J., Kenny, G. P., Prud'Homme, D. G., Malone, S. C., Wells, G. A., Scott, C. G., & Slovinec D'Angelo, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4963 · Cited by 554
The developmental origins of sarcopenia
Sayer, A. A., Syddall, H., Martin, H., Patel, H., Baylis, D., & Cooper, C. (2008) · The Journal of nutrition, health and aging · doi:10.1007/bf02982703 · Cited by 450
Buford, T. W., Anton, S. D., Judge, A. R., Marzetti, E., Wohlgemuth, S. E., Carter, C. S., Leeuwenburgh, C., Pahor, M., & Manini, T. M. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.04.004 · Cited by 295
HERR, H. W., & O’SULLIVAN, M. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67533-7 · Cited by 250
Cited by
Cormie, P., Galvão, D. A., Spry, N., Joseph, D., Chee, R., Taaffe, D. R., Chambers, S. K., & Newton, R. U. (2015) · BJU International · doi:10.1111/bju.12646 · Cited by 277
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
Schweizer, M. T., Antonarakis, E. S., Wang, H., Ajiboye, A. S., Spitz, A., Cao, H., Luo, J., Haffner, M. C., Yegnasubramanian, S., Carducci, M. A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010563 · Cited by 254
Winters-Stone, K. M., Dobek, J. C., Bennett, J. A., Dieckmann, N. F., Maddalozzo, G. F., Ryan, C. W., & Beer, T. M. (2015) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2014.08.010 · Cited by 126
Dawson, J. K., Dorff, T. B., Todd Schroeder, E., Lane, C. J., Gross, M. E., & Dieli-Conwright, C. M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4306-9 · Cited by 112
Metadata
- Authors
- Smith, M. R., Saad, F., Egerdie, B., Sieber, P. R., Tammela, T. L. J., Ke, C., Leder, B. Z., & Goessl, C.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-09-10
- Volume
- 30
- Issue
- 26
- Pages
- 3271-3276
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2064142663
- Cited by
- 196
- References
- 9
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer. https://app.cochat.ai/papers/10.1200/jco.2011.38.8850
- The paper
- Smith, M. R., Saad, F., Egerdie, B., Sieber, P. R., Tammela, T. L. J., Ke, C., Leder, B. Z., & Goessl, C. (2012). Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.38.8850
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.